We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Roche to Develop New Diagnostic Technologies for Traumatic Brain Injuries

By LabMedica International staff writers
Posted on 14 Oct 2024

Traumatic brain injuries (TBI) represent a significant global health issue, affecting approximately 69 million people each year. TBI occurs when an external force disrupts normal brain function, with severity ranging from mild (such as concussions) to moderate and severe forms. The effects of TBI can be long-lasting, potentially resulting in permanent disabilities. Individuals who suffer from TBI may experience a range of symptoms, including cognitive impairments, motor difficulties, emotional disturbances, and behavioral changes. The broader impact of TBI is felt not only by the patients themselves but also by their families, healthcare systems, and society, highlighting the need for improved management, support structures, and collaborative efforts to enhance patient outcomes. Unfortunately, studies indicate that TBI is often underdiagnosed or diagnosed too late, underscoring the need for quicker and more accurate diagnostic methods to facilitate timely and effective treatment.

To address these challenges, Roche Diagnostics (Basel, Switzerland) has entered into a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) Burn and Blast Medical Countermeasures Program to drive innovation in TBI diagnosis. Through this collaboration, Roche and BARDA aim to develop novel diagnostic technologies that address the widespread impact of TBI, as well as enhance healthcare system preparedness for mass casualty events. Currently, neuroimaging techniques like CT and MRI scans are the primary diagnostic tools for TBI, but these methods can be costly and may not be widely available in mass casualty scenarios. Additionally, neuroimaging alone is insufficient for diagnosing all types of TBI and predicting patient outcomes.


Image: The new partnership will explore development of solutions to aid the diagnosis of TBI (Photo courtesy of Roche)
Image: The new partnership will explore development of solutions to aid the diagnosis of TBI (Photo courtesy of Roche)

A major challenge lies in accurately stratifying patients with mild TBI to determine whether they require immediate intervention, further observation, or follow-up. A potential solution could be the development of a blood-based test, combined with clinical, physiological, or imaging data, to help healthcare professionals quickly identify and categorize TBI patients. Such a tool would enable earlier interventions, help prevent lasting damage, and improve the ability to predict patient outcomes and monitor treatment effectiveness. The goal of this partnership is to bring these innovations to market, potentially revolutionizing the way TBI is diagnosed and treated.

“We are honored to collaborate with BARDA on this important initiative,” said Life Cycle Leader Cardiometabolic and Neurology, Roche Diagnostics. “Our goal is to drive meaningful advancements in healthcare, ultimately enhancing patient care, outcomes and access. This partnership underscores our commitment to advancing medical diagnostics and addressing critical healthcare challenges such as scalable and accurate testing for traumatic brain injuries.

Related Links:
Roche Diagnostics


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Automated Blood Typing System
IH-500 NEXT
New
ELISA System
ABSOL HS DUO
New
UHF RFID Tag and Inlay
AD-321r6/AD-321r6-P

Latest Industry News

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests

CACLP 2025 New Date and Venue Announced